Truist analyst Michael Lewis lowered the firm’s price target on National Health Investors (NHI) to $72 from $78 and keeps a Hold rating on the shares. The firm is adjusting its model after the pullback in the stock price, though leaving its FFO multiple and net asset value premium relatively unchanged, the analyst tells investors in a research note. Truist adds it is positive on the REIT’s healthcare property type diversification, relatively high exposure to private payment for services from residents, a low-levered balance sheet, and an attractive well-covered dividend yield.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NHI:
- National Health Investors price target lowered to $76 from $80 at Wells Fargo
- National Health Investors price target lowered to $91 from $92 at BofA
- Navigating Risks: National Health Investors’ Potential Exposure in Forward Sale Agreements
- National Health Investors Reports Q3 2024 Results
- National Health Investors Founder W. Andrew Adams Retires
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
